Good news/bad news for Canadians living with arthritis, depending on where they live
Arthritis Consumer Experts (ACE) has released its Ninth Annual JointHealth™ Arthritis Medications Report Card with a clear message to the federal and provincial governments in Canada: Reimbursement access to arthritis medications has improved in many Canadian provinces, however, disappointing inequities remain in patient/physician choice and patient access to reimbursement for the medication prescribed for them by their rheumatologist.
“Thanks to the advocacy efforts of people living with arthritis and their rheumatologists, progress has been made in many Canadian provinces. We encourage the federal and provincial governments to maintain their commitment to the estimated 600,000 Canadians living with a type of autoimmune arthritis – rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis – and their right to choose with their healthcare team the therapy best suited to their disease biology, which is distinctly different from patient to patient,” said Cheryl Koehn, Founder and President, Arthritis Consumer Experts. Continue reading →
The JointHealth™ Arthritis Medications Report Card
How does your province compare?
During the last year, Arthritis Consumer Experts continuously monitored scientific and medication treatment advances that have the potential to affect the lives of those living with arthritis. The JointHealth™ Arthritis Medications Report Card summarizes and ranks these medication treatment advances and helps Canadians and their rheumatologists identify how their province measures up to other provinces in terms of providing reimbursement access to medications approved for autoimmune forms of arthritis.
The understanding of combination medication therapy allows people with arthritis to live healthier, more productive lives. To help prepare the arthritis consumer with the information they need to talk to their healthcare provider, this issue of JointHealth™monthly will also look at:
New arthritis medications on the horizon
The coast-to-coast discussion about a national pharmacare program
Take action now to improve your province’s drug formulary ranking
Tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis approved in Quebec.
As of June 1st, tofacitinib (Xeljanz®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.
Tofacitinib is an oral targeted small molecule medicine (TSMM) that was issued a Notice of Compliance (NOC) from Health Canada on April 17, 2014. Tofacitinib in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of RA, in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of tofacitinib as monotherapy.
Click here to view the most up-to-date version of ACE’s Report Card on provincial formulary reimbursement listings for biologic response modifiers.
LE COMITÉ ACE INTERROGE LES CANADIENS : COMMENT SE CLASSE VOTRE PROVINCE ?
La fiche-rapport du comité ACE aide les Canadiennes et Canadiens à évaluer leur accès au remboursement des médicaments contre l’arthrite
(Vancouver, BC ) — Dans sa 8e édition annuelle de sa fiche-rapport JointHealth™ sur les médicaments contre l’arthrite, le comité ACE (Arthritis Consumer Experts) indique que, selon leur lieu de résidence, les Canadiennes et Canadiens atteints d’une forme auto-immune d’arthrite ont accès à moins d’options de traitement ou peuvent avoir à « franchir plusieurs obstacles » avant d’être admissibles au remboursement des médicaments qui leur ont pourtant été prescrits par leur rhumatologue.
« Le comité ACE continue de lutter pour le respect des droits des personnes atteintes d’arthrite en prenant notamment les devants dans les revendications concernant l’accès équitable et en temps opportun au remboursement des médicaments contre l’arthrite par les régimes publics et privés d’assurance-médicaments. Les études ont démontré qu’un budget plus consistant dans le remboursement des médicaments contre la polyarthrite rhumatoïde dans la dernière décennie a entraîné une baisse du taux d’hospitalisation, un meilleur état fonctionnel des patients et une plus faible incidence d’incapacité au travail » souligne Cheryl Koehn, fondatrice et présidente du comité ACE.
(Vancouver, BC) — In its eighth annual JointHealth™ Arthritis Medications Report Card, Arthritis Consumer Experts (ACE) reports that, depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist.
“ACE continues to fight for the rights of people with arthritis, which includes our leadership on timely and equitable reimbursement access to arthritis medications on public and private drug formularies. Studies have found that increases in medication treatment costs for rheumatoid arthritis over the last decade are associated with lower hospitalization rates, better functional status and a lower incidence of work disability,” said Cheryl Koehn, Founder and President of Arthritis Consumer Experts.
The JointHealth™ Arthritis Medications Report Card: How Does Your Province Measure Up?
While there are no cures for arthritis, scientific advances and improved treatments, along with a better understanding of combination medication therapy, are allowing people with arthritis to live healthier, more productive lives. In the last year, advances in arthritis treatment include the expansion of two new classes of medications used to treat autoimmune forms of arthritis. This year’s JointHealth™ Arthritis Medications Report Card reflects this change and covers three medication categories – biologic response modifiers, subsequent entry biologics, and targeted small molecule medications – increasing the number of individual arthritis medications evaluated in the Report Card to 13.